Media stories about Ovid Therapeutc (NASDAQ:OVID) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ovid Therapeutc earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.4396093506153 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Stand Up to “Bully” Trump: Bio CEOs Levin, Holtzman Call to Their Peers (xconomy.com)
- Composite Index Top 20 Leading Companies Today (fxpips.com)
- Ovid Therapeutics : Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies (4-traders.com)
- BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935 (in.reuters.com)
- Ovid Therapeutics Announces First Patient Randomized in Clinical Trial (investingnews.com)
Several research firms have commented on OVID. Cowen and Company began coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They issued an “outperform” rating on the stock. Citigroup Inc. began coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They issued a “buy” rating and a $21.00 price target on the stock. Zacks Investment Research lowered shares of Ovid Therapeutc from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. William Blair began coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They issued an “outperform” rating on the stock. Finally, JMP Securities began coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They issued an “outperform” rating and a $26.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Ovid Therapeutc currently has an average rating of “Buy” and a consensus target price of $23.50.
Shares of Ovid Therapeutc (NASDAQ:OVID) opened at 7.19 on Friday. The stock’s market capitalization is $176.88 million. The firm has a 50-day moving average of $7.94 and a 200 day moving average of $10.62. Ovid Therapeutc has a 12-month low of $5.28 and a 12-month high of $15.93.
Ovid Therapeutc (NASDAQ:OVID) last issued its earnings results on Thursday, August 10th. The company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.09. Equities analysts forecast that Ovid Therapeutc will post ($3.88) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Ovid Therapeutc (OVID) Earning Somewhat Favorable Press Coverage, Report Shows” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://stocknewstimes.com/2017/08/26/ovid-therapeutc-ovid-earning-somewhat-favorable-press-coverage-report-shows.html.
Ovid Therapeutc Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.
